SEC EDGARJul 31$PGEN

Thomasian Harry Jr. sold $606K of PGEN

Thomasian Harry Jr. (Chief Financial Officer) sold 100,000 shares of PRECIGEN, INC. (PGEN) at $6.06 ($0.61M total) on 2026-07-31 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Thomasian Harry Jr.

Published Jul 31, 2026, 8:26 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jul 31, 2026, 8:37 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$PGEN

Neutral

medium confidence

Mentioned

$PGEN

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$PGENNeutralLow

Why it matters

The disclosure provides a new, timestamped data point on insider selling activity, but it does not include any new company-specific operating, financial, or regulatory catalyst.

Market read

Traders may monitor PGEN for follow-on insider activity, but the filing alone is unlikely to drive a durable repricing without corroborating fundamentals.

What to watch

The article does not state total insider ownership changes beyond the post-transaction share count, nor does it provide sales frequency or prior Form 4 patterns.

Relevance 4/10Novelty 3/10Timing: filed 2026-07-31, after-hours SEC Form 4 disclosure

Background

The article is a primary-source SEC Form 4 insider transaction for Precigen, Inc. (PGEN).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PGENNeutralMedium confidence

Context

Precigen CFO Thomasian Harry Jr. filed a Form 4 open-market sale of 100,000 shares at $6.06 on 2026-07-31 under a 10b5-1 plan.

Expected impact

Likely limited, short-lived sentiment impact; any move would be small unless accompanied by other news.

Evidence & confidence

The filing is a routine 10b5-1 planned sale with no accompanying operational or guidance change disclosed in the text.

Market effects

Sector

Minimal. Insider selling in a single biotech does not materially reset sector risk without additional context.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

issuer
PRECIGEN, INC.
Company whose CFO insider sale is disclosed via SEC Form 4.
insider
Thomasian Harry Jr.
CFO reporting an open-market sale of 100,000 shares under a 10b5-1 plan.

Read at source ← All news

$PGENMedAI 8/10

Precigen Sinks 26% as Inovio Wins FDA Approval for Papzimeos Rival Days Before Earnings

Precigen (PGEN) shares dropped 26% after Inovio (INO) received FDA approval for Voceryq, a rival to Precigen's Papzimeos. Voceryq offers easier dosing, though Papzimeos showed stronger trial results. Precigen reports Q3 earnings on November 4, with analysts expecting $236M in 2026 revenue.

finance.yahoo.comNov 2

$PGENHighAI 9/10

PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings

Precigen (PGEN) shares dropped 20% premarket after Inovio's (INO) FDA-approved rival treatment, Voceryq, challenged Papzimeos. PGEN reported $53.1M Q2 revenue. Retail investors remain optimistic about a potential buyout. Voceryq expects shipments in 60 days, with full deployment in early 2027. Clinical trials showed higher surgery-free rates for Papzimeos (51%) vs. Voceryq (27%).

finance.yahoo.comNov 2

$INOHighAI 9/10

FDA Grants Accelerated Approval to Inovio's DNA Immunotherapy Voceryq; Precigen Shares Plunge 27% After Hours

FDA granted accelerated approval to Inovio's (INO) DNA immunotherapy Voceryq for recurrent respiratory papillomatosis. Inovio shares surged 300% after hours, while Precigen's (PGEN) shares dropped 27% on market competition concerns. Voceryq is the first plasmid DNA-based immunotherapy approved in the U.S. and the second treatment for the disease.

finance.biggo.comOct 30

$PGENMedAI 8/10

Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?

Precigen (PGEN) received FDA Platform Technology Designation for AdenoVerse, the technology behind PAPZIMEOS. The designation may reduce development costs for future drugs, including PRGN-2009, an investigational cancer treatment. Management expects benefits but has not quantified cost savings or timelines. The FDA's draft guidance outlines potential benefits, but Precigen must provide supporting evidence for reuse of prior data. Hedge fund sentiment showed a slight decrease in holdings.

insidermonkey.comSep 29

$PGENHighAI 8/10

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

Precigen, Inc. (PGEN) announced that the FDA granted platform technology designation to its AdenoVerse® immunotherapeutic platform, used in its commercial product PAPZIMEOS®. This designation may accelerate the development of future therapies by leveraging existing data and reducing duplicative work. The company's CEO highlighted the potential benefits for its clinical portfolio, including PRGN-2009 for HPV-associated cancers.

prnewswire.comSep 21

$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

pro.thestreet.comAug 21